請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71517完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 潘敏雄(Min-Hsiung Pan) | |
| dc.contributor.author | Pei-Yu Chen | en |
| dc.contributor.author | 陳佩妤 | zh_TW |
| dc.date.accessioned | 2021-06-17T06:02:18Z | - |
| dc.date.available | 2024-02-14 | |
| dc.date.copyright | 2019-02-14 | |
| dc.date.issued | 2019 | |
| dc.date.submitted | 2019-01-30 | |
| dc.identifier.citation | 1. O'Connor, S.; Taylor, C.; Campbell, L. A.; Epstein, S.; Libby, P. Potential infectious etiologies of atherosclerosis: A multifactorial perspective. Emerg. Infect. Dis. 2001, 7, (5), 780-788.
2. Li, Y. H.; Ueng, K. C.; Jeng, J. S.; Charng, M. J.; Lin, T. H.; Chien, K. L.; Wang, C. Y.; Chao, T. H.; Liu, P. Y.; Su, C. H.; Chien, S. C.; Liou, C. W.; Tang, S. C.; Lee, C. C.; Yu, T. Y.; Chen, J. W.; Wu, C. C.; Yeh, H. I.; Lipid, W. G. T. 2017 Taiwan lipid guidelines for high risk patients. J. Formos. Med. Assoc. 2017, 116, (4), 217-248. 3. Pan, W. H.; Chiang, B. N. Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan - A unique experience. Atherosclerosis. 1995, 118, (2), 285-295. 4. Ross, R. Atherosclerosis — An inflammatory disease. New Engl. J. Med. 1999, 340, (2), 115-126. 5. Koenig, W.; Khuseyinova, N. Biomarkers of atherosclerotic plaque instability and rupture. Arterioscl. Throm. Vas. 2007, 27, (1), 15-26. 6. Shah, P. K. Mechanisms of plaque vulnerability and rupture. J. Am. Coll. Cardiol. 2003, 41, (4 Suppl S), 15S-22S. 7. Jessup, W.; Krithairides, L.; Stocker, R. Lipid oxidation in atherogenesis: an overview. Biochem. Soc. Trans. 2004, 32, (1), 134-138. 8. Huber, S. A.; Sakkinen, P.; Conze, D.; Hardin, N.; Tracy, R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscl. Throm. Vas. 1999, 19, (10), 2364-2367. 9. Stocker, C. J.; Sugars, K. L.; Harari, O. A.; Landis, R. C.; Morley, B. J.; Haskard, D. O. TNF-alpha, IL-4, and IFN-gamma regulate differential expression of P and E-selectin expression by porcine aortic endothelial cells. J. Immunol. 2000, 164, (6), 3309-3315. 10. Cybulsky, M. I.; Gimbrone, M. A. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science. 1991, 251, (4995), 788-791. 11. Galkina, E.; Ley, K. Vascular adhesion molecules in atherosclerosis. Arterioscl. Throm. Vas. 2007, 27, (11), 2292-2301. 12. Adams, D. H.; Shaw, S. Leucocyte-endothelial interactions and regulation of leucocyte migration. Lancet. 1994, 343, (8901), 831-836. 13. Kawakami, A.; Aikawa, M.; Alcaide, P.; Luscinskas, F. W.; Libby, P.; Sacks, F. M. Apolipoprotein CIII induces expression of vascular cell adhesion molecule-1 in vascular endothelial cells and increases adhesion of monocytic cells. Circulation. 2006, 114, (7), 681-687. 14. Della Rocca, D. G.; Pepine, C. J. Endothelium as a predictor of adverse outcomes. Clin. Cardiol. 2010, 33, (12), 730-732. 15. Wang, Z.; Klipfell, E.; Bennett, B. J.; Koeth, R. A.; Levison, B. S.; Dugar, B.; Feldstein, A. E.; Britt, E. B.; Fu, X.; Chung, Y. M.; Wu, Y.; Schauer, P.; Smith, J. D.; Allayee, H.; Tang, W. H.; DiDonato, J. A.; Lusis, A. J.; Hazen, S. L. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 2011, 472, (7341), 57-63. 16. Tang, W. H.; Wang, Z. E.; Levison, B. S.; Koeth, R. A.; Britt, E. B.; Fu, X. M.; Wu, Y. P.; Hazen, S. L. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. New Engl. J. Med. 2013, 368, (17), 1575-1584. 17. Seldin, M. M.; Meng, Y. H.; Qi, H. X.; Zhu, W. F.; Wang, Z. E.; Hazen, S. L.; Lusis, A. J.; Shih, D. M. Trimethylamine-N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-kappa B. J. Am. Heart Assoc. 2016, 5, (2), e002767. 18. Ma, G. H.; Pan, B.; Chen, Y.; Guo, C. X.; Zhao, M. M.; Zheng, L. M.; Chen, B. X. Trimethylamine-N-oxide in atherogenesis: impairing endothelial self-repair capacity and enhancing monocyte adhesion. Biosci. Rep. 2017, 37. 19. Hu, Y.; Zhao, Y.; Yuan, L.; Yang, X. Protective effects of tartary buckwheat flavonoids on high TMAO diet-induced vascular dysfunction and liver injury in mice. Food Funct. 2015, 6, (10), 3359-72. 20. Zhu, W. F.; Gregory, J. C.; Org, E.; Buffa, J. A.; Gupta, N.; Wang, Z. N.; Li, L.; Fu, X. M.; Wu, Y. P.; Mehrabian, M.; Sartor, R. B.; McIntyre, T. M.; Silverstein, R. L.; Tang, W. H.; DiDonato, J. A.; Brown, J. M.; Lusis, A. J.; Hazen, S. L. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016, 165, (1), 111-124. 21. Liu, T. X.; Niu, H. T.; Zhang, S. Y. Intestinal microbiota metabolism and atherosclerosis. Chin. Med. J. 2015, 128, (20), 2805-2811. 22. Koeth, R. A.; Wang, Z. E.; Levison, B. S.; Buffa, J. A.; Org, E.; Sheehy, B. T.; Britt, E. B.; Fu, X. M.; Wu, Y. P.; Li, L.; Smith, J. D.; DiDonato, J. A.; Chen, J.; Li, H. Z.; Wu, G. D.; Lewis, J. D.; Warrier, M.; Brown, J. M.; Krauss, R. M.; Tang, W. H.; Bushman, F. D.; Lusis, A. J.; Hazen, S. L. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 2013, 19, (5), 576-585. 23. Sun, X.; Jiao, X.; Ma, Y.; Liu, Y.; Zhang, L.; He, Y.; Chen, Y. Trimethylamine-N-oxide induces inflammation and endothelial dysfunction in human umbilical vein endothelial cells via activating ROS-TXNIP-NLRP3 inflammasome. Biochem. Biophys. Res. Commun. 2016, 481, (1-2), 63-70. 24. Chen, M. L.; Zhu, X. H.; Ran, L.; Lang, H. D.; Yi, L.; Mi, M. T. Trimethylamine-N-oxide induces vascular inflammation by activating the NLRP3 inflammasome through the SIRT3-SOD2-mtROS signaling pathway. J. Am. Heart Assoc. 2017, 6, (9), e006347. 25. Dore, J.; Simren, M.; Buttle, L.; Guarner, F. Hot topics in gut microbiota. United Eur. Gastroent. 2013, 1, (5), 311-318. 26. Lee, W. J.; Hase, K. Gut microbiota-generated metabolites in animal health and disease. Nat. Chem. Biol. 2014, 10, (6), 416-424. 27. Conlon, M. A.; Bird, A. R. The impact of diet and lifestyle on gut microbiota and human health. Nutrients. 2015, 7, (1), 17-44. 28. He, Z.; Chen, Z. Y. The origin of trimethylamine-N-oxide (TMAO) and its role in development of atherosclerosis. J. Food Bioact. 2018, 2, 28-36. 29. Parkin, K. L.; Hultin, H. O. Fish muscle microsomes catalyze the conversion of trimethylamine oxide to dimethylamine and formaldehyde. FEBS Lett. 1982, 139, (1), 61-64. 30. Meadows, J. A.; Wargo, M. J. Carnitine in bacterial physiology and metabolism. Microbiology. 2015, 161, (6), 1161-1174. 31. Pekala, J.; Patkowska-Sokola, B.; Bodkowski, R.; Jamroz, D.; Nowakowski, P.; Lochynski, S.; Librowski, T. L-Carnitine - metabolic functions and meaning in humans life. Curr. Drug Metab. 2011, 12, (7), 667-678. 32. Flanagan, J. L.; Simmons, P. A.; Vehige, J.; Willcox, M. D. P.; Garrett, Q. Role of carnitine in disease. Nutr. Metab. (Lond.). 2010, 7, (1), 30. 33. Rebouche, C. J.; Chenard, C. A. Metabolic-fate of dietary carnitine in human adults - identification and quantification of urinary and fecal metabolites. J. Nutr. 1991, 121, (4), 539-546. 34. Zhu, Y. J.; Jameson, E.; Crosatti, M.; Schafer, H.; Rajakumar, K.; Bugg, T. D. H.; Chen, Y. Carnitine metabolism to trimethylamine by an unusual Rieske-type oxygenase from human microbiota. Proc. Natl. Acad. Sci. U. S. A. 2014, 111, (11), 4268-4273. 35. Seim, H.; Löster, H.; Claus, R.; Kleber, H. P.; Strack, E. Splitting of the C-N bond in carnitine by an enzyme (trimethylamine forming) from membranes of Acinetobacter calcoaceticus. FEMS Microbiol. Lett. 1982, 15, (3), 165-167. 36. Romano, K. A.; Vivas, E. I.; Amador-Noguez, D.; Rey, F. E. Intestinal microbiota composition modulates choline bioavailability from diet and accumulation of the proatherogenic metabolite trimethylamine-N-oxide. mBio. 2015, 6, (2), e02481-14. 37. Rath, S.; Heidrich, B.; Pieper, D. H.; Vital, M. Uncovering the trimethylamine-producing bacteria of the human gut microbiota. Microbiome. 2017, 5, (1), 54. 38. Krueger, S. K.; Williams, D. E. Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism. Pharmacol. Ther. 2005, 106, (3), 357-387. 39. Siddens, L. K.; Henderson, M. C.; VanDyke, J. E.; Williams, D. E.; Krueger, S. K. Characterization of mouse flavin-containing monooxygenase transcript levels in lung and liver, and activity of expressed isoforms. Biochem. Pharmacol. 2008, 75, (2), 570-579. 40. Bennett, B. J.; Vallim, T. Q. D.; Wang, Z. N.; Shih, D. M.; Meng, Y. H.; Gregory, J.; Allayee, H.; Lee, R.; Graham, M.; Crooke, R.; Edwards, P. A.; Hazen, S. L.; Lusis, A. J. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 2013, 17, (1), 49-60. 41. Treacy, E. P.; Akerman, B. R.; Chow, L. M. L.; Youil, R.; Bibeau, C.; Lin, J.; Bruce, A. G.; Knight, M.; Danks, D. M.; Cashman, J. R.; Forrest, S. M. Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication. Hum. Mol. Genet. 1998, 7, (5), 839-845. 42. Banikazemi, Z.; Haji, H. A.; Mohammadi, M.; Taheripak, G.; Iranifar, E.; Poursadeghiyan, M.; Moridikia, A.; Rashidi, B.; Taghizadeh, M.; Mirzaei, H. Diet and cancer prevention: Dietary compounds, dietary microRNAs, and dietary exosomes. J. Cell. Biochem. 2018, 119, (1), 185-196. 43. Cardona, F.; Andres-Lacueva, C.; Tulipani, S.; Tinahones, F. J.; Queipo-Ortuno, M. I. Benefits of polyphenols on gut microbiota and implications in human health. J. Nutr. Biochem. 2013, 24, (8), 1415-1422. 44. Qiao, Y.; Sun, J.; Xia, S. F.; Tang, X.; Shi, Y. H.; Le, G. W. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct. 2014, 5, (6), 1241-1249. 45. Chen, M. L.; Yi, L.; Zhang, Y.; Zhou, X.; Ran, L.; Yang, J. N.; Zhu, J. D.; Zhang, Q. Y.; Mi, M. T. Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota. mBio. 2016, 7, (2), e02210-15. 46. Kapetanovic, I. M.; Muzzio, M.; Huang, Z. H.; Thompson, T. N.; McCormick, D. L. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2011, 68, (3), 593-601. 47. Etxeberria, U.; Hijona, E.; Aguirre, L.; Milagro, F. I.; Bujanda, L.; Rimando, A. M.; Martinez, J. A.; Portillo, M. P. Pterostilbene-induced changes in gut microbiota composition in relation to obesity. Mol. Nutr. Food Res. 2017, 61, (1). 48. Fabjan, N.; Rode, J.; Kosir, I. J.; Wang, Z. H.; Zhang, Z.; Kreft, I. Tartary buckwheat (Fagopyrum tataricum Gaertn.) as a source of dietary rutin and quercitrin. J. Agric. Food Chem. 2003, 51, (22), 6452-6455. 49. Fusi, F.; Saponara, S.; Pessina, F.; Gorelli, B.; Sgaragli, G. Effects of quercetin and rutin on vascular preparations - A comparison between mechanical and electrophysiological phenomena. Eur. J. Nutr. 2003, 42, (1), 10-17. 50. Bhaskar, S.; Kumar, K. S.; Krishnan, K.; Antony, H. Quercetin alleviates hypercholesterolemic diet induced inflammation during progression and regression of atherosclerosis in rabbits. Nutrition. 2013, 29, (1), 219-229. 51. Yung, L. M.; Leung, F. P.; Wong, W. T.; Tian, X. Y.; Yung, L. H.; Chen, Z. Y.; Yao, X. Q.; Huang, Y. Tea polyphenols benefit vascular function. Inflammopharmacology. 2008, 16, (5), 230-234. 52. Liu, Z. B.; Chen, Z. C.; Guo, H. W.; He, D. P.; Zhao, H. R.; Wang, Z. Y.; Zhang, W.; Liao, L.; Zhang, C.; Ni, L. The modulatory effect of infusions of green tea, oolong tea, and black tea on gut microbiota in high-fat-induced obese mice. Food Funct. 2016, 7, (12), 4869-4879. 53. Seo, D. B.; Jeong, H. W.; Cho, D.; Lee, B. J.; Lee, J. H.; Choi, J. Y.; Bae, I. H.; Lee, S. J. Fermented green tea extract alleviates obesity and related complications and alters gut microbiota composition in diet-induced obese mice. J. Med. Food. 2015, 18, (5), 549-556. 54. Chen, Y. H.; Zhang, X.; Cheng, L.; Zheng, X. J.; Zhang, Z. C. The evaluation of the quality of Feng Huang Oolong teas and their modulatory effect on intestinal microbiota of high-fat diet-induced obesity mice model. Int. J. Food Sci. Nutr. 2018, 69, (7), 842-856. 55. Liu, P. L.; Liu, J. T.; Kuo, H. F.; Chong, I. W.; Hsieh, C. C. Epigallocatechin gallate attenuates proliferation and oxidative stress in human vascular smooth muscle cells induced by interleukin-1 beta via heme oxygenase-1. Mediators Inflamm. 2014. 56. Babu, P. V. A.; Si, H. W.; Liu, D. M. Epigallocatechin gallate reduces vascular inflammation in db/db mice possibly through an NF-kappa B-mediated mechanism. Mol. Nutr. Food Res. 2012, 56, (9), 1424-1432. 57. Weerawatanakorn, M.; Hung, W. L.; Pan, M. H.; Li, S.; Li, D.; Wan, X.; Ho, C. T. Chemistry and health beneficial effects of oolong tea and theasinensins. Food Sci. Hum. Wellness. 2015, 4, (4), 133-146. 58. Li, S. M.; Pan, M. H.; Lo, C. Y.; Tan, D.; Wang, Y.; Shahidi, F.; Ho, C. T. Chemistry and health effects of polymethoxyflavones and hydroxylated polymethoxyflavones. J. Funct. Foods. 2009, 1, (1), 2-12. 59. Duan, L.; Dou, L. L.; Yu, K. Y.; Guo, L.; Chen, B. Z.; Li, P.; Liu, E. H. Polymethoxyflavones in peel of Citrus reticulata 'Chachi' and their biological activities. Food Chem. 2017, 234, 254-261. 60. Wu, J. C.; Tsai, M. L.; Lai, C. S.; Lo, C. Y.; Ho, C. T.; Wang, Y. J.; Pan, M. H. Polymethoxyflavones prevent benzo[a]pyrene/dextran sodium sulfate-induced colorectal carcinogenesis through modulating xenobiotic metabolism and ameliorate autophagic defect in ICR mice. Int. J. Cancer. 2018, 142, (8), 1689-1701. 61. Lai, C. S.; Wu, J. C.; Ho, C. T.; Pan, M. H. Disease chemopreventive effects and molecular mechanisms of hydroxylated polymethoxyflavones. BioFactors. 2015, 41, (5), 301-313. 62. Su, J. D.; Yen, J. H.; Li, S. M.; Weng, C. Y.; Lin, M. H.; Ho, C. T.; Wu, M. J. 3 ',4 '-Didemethylnobiletin induces phase II detoxification gene expression and modulates PI3K/Akt signaling in PC12 cells. Free Radical Biol. Med. 2012, 52, (1), 126-141. 63. Gosslau, A.; Chen, K. Y.; Ho, C. T.; Li, S. Anti-inflammatory effects of characterized orange peel extracts enriched with bioactive polymethoxyflavones. Food Sci. Hum. Wellness. 2014, 3, (1), 26-35. 64. Whitman, S. C.; Kurowska, E. M.; Manthey, J. A.; Daugherty, A. Nobiletin, a citrus flavonoid isolated from tangerines, selectively inhibits class A scavenger receptor-mediated metabolism of acetylated LDL by mouse macrophages. Atherosclerosis. 2005, 178, (1), 25-32. 65. Li, S. M.; Lo, C. Y.; Ho, C. T. Hydroxylated polymethoxyflavones and methylated flavonoids in sweet orange (Citrus sinensis) peel. J. Agric. Food Chem. 2006, 54, (12), 4176-4185. 66. Boutagy, N. E.; Neilson, A. P.; Osterberg, K. L.; Smithson, A. T.; Englund, T. R.; Davy, B. M.; Hulver, M. W.; Davy, K. P. Probiotic supplementation and trimethylamine-N-oxide production following a high-fat diet. Obesity. 2015, 23, (12), 2357-2363. 67. Degirolamo, C.; Rainaldi, S.; Bovenga, F.; Murzilli, S.; Moschetta, A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014, 7, (1), 12-18. 68. Lai, C. S.; Tsai, M. L.; Cheng, A. C.; Li, S. M.; Lo, C. Y.; Wang, Y.; Xiao, H.; Ho, C. T.; Wang, Y. J.; Pan, M. H. Chemoprevention of colonic tumorigenesis by dietary hydroxylated polymethoxyflavones in azoxymethane-treated mice. Mol. Nutr. Food Res. 2011, 55, (2), 278-290. 69. Reikvam, D. H.; Erofeev, A.; Sandvik, A.; Grcic, V.; Jahnsen, F. L.; Gaustad, P.; McCoy, K. D.; Macpherson, A. J.; Meza-Zepeda, L. A.; Johansen, F. E. Depletion of murine intestinal microbiota: Effects on gut mucosa and epithelial gene expression. PLoS One. 2011, 6, (3), e17996. 70. Wang, H.; Zhang, L.; Wang, L. P.; Zhou, Q. N.; Wang, H. L.; Hou, Y. M.; Ma, Y. T. Pterostilbene suppresses vascular adhesion molecule expression in TNF-alpha-stimulated vascular muscle cells. Int. J. Clin. Exp. Pathol. 2016, 9, (2), 1432-1438. 71. Liang, W. B.; Lee, A. H.; Binns, C. W.; Huang, R. S.; Hu, D. L.; Zhou, Q. K. Tea consumption and ischemic stroke risk: A case-control study in southern China. Stroke. 2009, 40, (7), 2480-2485. 72. Spencer, M. D.; Hamp, T. J.; Reid, R. W.; Fischer, L. M.; Zeisel, S. H.; Fodor, A. A. Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency. Gastroenterology. 2011, 140, (3), 976-986. 73. Serino, M.; Blasco-Baque, V.; Nicolas, S.; Burcelin, R. Far from the eyes, close to the heart: Dysbiosis of gut microbiota and cardiovascular consequences. Curr. Cardiol. Rep. 2014, 16, (11), 540. 74. Goldsmith, J. R.; Sartor, R. B. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J. Gastroenterol. 2014, 49, (5), 785-798. 75. Wu, W. K.; Chen, C. C.; Liu, P. Y.; Panyod, S.; Liao, B. Y.; Chen, P. C.; Kao, H. L.; Kuo, H. C.; Kuo, C. H.; Chiu, H. T.; Chen, R. A.; Chuang, H. L.; Huang, Y. T.; Zou, H. B.; Hsu, C. C.; Chang, T. Y.; Lin, C. L.; Ho, C. T.; Yu, H. T.; Sheen, L. Y.; Wu, M. S. Identification of TMAO-producer phenotype and host–diet–gut dysbiosis by carnitine challenge test in human and germ-free mice. Gut. 2018. 76. Wang, Z.; Roberts, A. B.; Buffa, J. A.; Levison, B. S.; Zhu, W.; Org, E.; Gu, X.; Huang, Y.; Zamanian-Daryoush, M.; Culley, M. K.; DiDonato, A. J.; Fu, X.; Hazen, J. E.; Krajcik, D.; DiDonato, J. A.; Lusis, A. J.; Hazen, S. L. Non-lethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell. 2015, 163, (7), 1585-1595. 77. Roberts, A. B.; Gu, X. D.; Buffa, J. A.; Hurd, A. G.; Wang, Z. N.; Zhu, W. F.; Gupta, N.; Skye, S. M.; Cody, D. B.; Levison, B. S.; Barrington, W. T.; Russell, M. W.; Reed, J. M.; Duzan, A.; Lang, J. M.; Fu, X. M.; Li, L.; Myers, A. J.; Rachakonda, S.; Didonato, J. A.; Brown, J. M.; Gogonea, V.; Lusis, A. J.; Garcia-Garcia, J. C.; Hazen, S. L. Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat. Med. 2018, 24, (9), 1407-1417. 78. Tippani, R.; Prakhya, L. J. S.; Porika, M.; Sirisha, K.; Abbagani, S.; Thammidala, C. Pterostilbene as a potential novel telomerase inhibitor: Molecular docking studies and its in vitro evaluation. Curr. Pharm. Biotechnol. 2013, 14, (12), 1027-1035. 79. Shih, D. M.; Wang, Z. N.; Lee, R.; Meng, Y. H.; Che, N.; Charugundla, S.; Qi, H.; Wu, J.; Pan, C.; Brown, J. M.; Vallim, T.; Bennett, B. J.; Graham, M.; Hazen, S. L.; Lusis, A. J. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 2015, 56, (1), 22-37. 80. Warrier, M.; Shih, D. M.; Burrows, A. C.; Ferguson, D.; Gromovsky, A. D.; Brown, A. L.; Marshall, S.; McDaniel, A.; Schugar, R. C.; Wang, Z. E.; Sacks, J.; Rong, X.; Vallim, T. D.; Chou, J.; Ivanova, P. T.; Myers, D. S.; Brown, H. A.; Lee, R. G.; Crooke, R. M.; Graham, M. J.; Liu, X. L.; Parini, P.; Tontonoz, P.; Lusis, A. J.; Hazen, S. L.; Temel, R. E.; Brown, J. M. The TMAO-generating enzyme flavin monooxygenase 3 is a central regulator of cholesterol balance. Cell Reports. 2015, 10, (3), 326-338. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/71517 | - |
| dc.description.abstract | 據統計，心血管疾病為全球人口最常見的的發病原因，並且是全世界十大死因的第一名。動脈粥狀硬化是造成心血管疾病的主要原因，已被視為工業化國家的公共衛生問題。 近年來，氧化三甲胺 (trimethylamine-N-oxide, TMAO)被認為會導致動脈粥狀硬化，並與心血管疾病有很強的相關性。TMAO是由膳食中的肉鹼(carnitine)經由腸道菌代謝成三甲胺 (trimethylamine, TMA)，隨後再經宿主的肝臟酵素flavin monooxygenases (FMOs)氧化成TMAO。本研究的目的是想探討多酚類化合物 (pterostilbene, oolong tea extract and PMFs)對於TMAO生成及減緩血管發炎之效果。結果顯示，相較於控制組，單獨給予1.3 %肉鹼飲用水的組別顯著性的增加了血漿中TMAO的含量；而給予多酚類化合物的小鼠，則可以降低肉鹼所引起的血漿中TMAO上升的現象。此外，相較於單獨給予肉鹼的組別，給予多酚類化合物的小鼠，其肝臟酵素FMO3的mRNA表現量都有顯著性的下降。採集動脈進行血管發炎因子 (TNF-α, VCAM-1 and E-selectin) mRNA表現量測定，結果顯示給予本篇使用的多酚類化合物之小鼠可以減緩血管的發炎。相較於單獨給予肉鹼的組別，PMFs顯著地降低了VCAM-1 mRNA表現量，而給予pterostilbene以及烏龍茶萃取物的組別則顯著性降低了TNF-α, VCAM-1和E-selectin mRNA表現量。經腸道菌分析結果顯示，三種多酚類化合物的給予都增加了類桿菌屬的相對豐富。而給予烏龍茶萃取物的組別，則可增加乳桿菌屬的相對豐富。艾克曼菌 (Akkermansia)則是在給予polymethoxyflavones的組別有觀察到增加的現象。綜合以上結果，此三種多酚類化合物可以經由調節腸道菌相以及降低肝臟酵素FMO3而達到減緩血管發炎的作用。 | zh_TW |
| dc.description.abstract | Cardiovascular disease (CVD) has become a ubiquitous cause of morbidity and a leading contributor to mortality in most countries. Atherosclerosis, a major component of CVD, has properly been considered a public health problem of industrialized countries. Trimethylamine-N-oxide (TMAO) was recently discovered as a proatherogenic species which is generated from dietary carnitine through gut microbiota-dependent pathway. Carnitine, a dietary quaternary amine, has been identified to specifically metabolize to trimethylamine (TMA) by gut microbiota and subsequently oxidize to TMAO by host hepatic enzymes, flavin monooxygenases (FMOs). The objective of this study aims to investigate the effects of dietary phenolic compounds (pterostilbene, oolong tea extract and polymethoxyflavones mixture) on reducing TMAO formation and on reversing vascular inflammation in carnitine-feeding mice. Our studies used LC-MS/MS to detect plasma TMAO and the results showed that mice treated with 1.3% carnitine in drinking water significantly (p < 0.05) increased the plasma levels of TMAO compared to control group; and these three phenolic compounds can reverse it. Meanwhile, these dietary phenolic compounds significantly (p < 0.05) decreased hepatic FMO3 mRNA levels compared to carnitine only group. Additionally, these dietary compounds decreased mRNA levels of vascular inflammatory markers (TNF-α, VCAM-1 and E-selectin). We analyzed the taxonomic compositions of the microbiota using 16S rRNA gene sequencing of DNA extracted from the cecal samples. It has been found that these three dietary compounds can modulate the growth of certain gut microbiota in vivo. Genus-level analysis showed that these three dietary phenolic compounds induced an increase in the relative abundances of Bacteroides. Oolong tea extract-treated group up-regulated Lactobacillus genus, compared to carnitine only group. Administration of polymethoxyflavones mixture increased Akkermansia in mice. In conclusion, pterostilbene, oolong tea extract and polymethoxyflavones have protective effects against carnitine feeding-induced vascular inflammation by gut microbiota remodeling and decreased TMAO levels through hepatic FMO3 mRNA reduction. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-17T06:02:18Z (GMT). No. of bitstreams: 1 ntu-108-R05445134-1.pdf: 3212243 bytes, checksum: 92fafb0e10c17899dfa33f2711e547f6 (MD5) Previous issue date: 2019 | en |
| dc.description.tableofcontents | 謝誌 i
中文摘要 iii Abstract v Table of contents vii List of figures ix List of tables x Abbreviations xi Introduction 1 1. Literature review 2 1.1 Atherosclerosis and cardiovascular disease 2 1.2 Trimethylamine-N-oxide (TMAO) is associated with atherosclerosis through inducing vascular inflammation and endothelial dysfunction 6 1.3 The enzymes contributed to metabolize carnitine to TMAO 12 1.4 Natural compounds in TMAO research and other attractive natural bioactive compounds 17 2. Objectives and experimental design 26 2.1 Objectives 26 2.2 Experimental design 26 3. Materials and Methods 29 3.1 Materials 29 3.2 Methods 31 4. Results and discussions 40 4.1 Effects of treatments on body weight, daily intake and organ weight in C57BL/6 mice 40 4.2 Natural dietary compounds inhibit plasma TMAO elevation induced by chronic L-carnitine feeding 42 4.3 Natural dietary compounds reverse chronic L-carnitine feeding-induced vascular inflammation in C57BL/6 mice 45 4.4 Effects of natural dietary compounds on intestinal microbiota composition 47 4.5 Microbial enzyme cntA/B may be an insufficient marker for TMAO production 49 4.6 Natural dietary compounds inhibit TMAO synthesis by reducing hepatic FMO3 mRNA expression levels 51 5. Conclusion 54 6. Figures 55 7. Tables 68 References 69 | |
| dc.language.iso | en | |
| dc.subject | 肉鹼 | zh_TW |
| dc.subject | 動脈粥狀硬化 | zh_TW |
| dc.subject | 氧化三甲胺 (TMAO) | zh_TW |
| dc.subject | 膳食化合物 | zh_TW |
| dc.subject | 腸道菌 | zh_TW |
| dc.subject | Dietary phenolic compounds | en |
| dc.subject | Trimethylamine-N-oxide (TMAO) | en |
| dc.subject | Carnitine | en |
| dc.subject | Gut microbiota | en |
| dc.subject | Flavin monooxygenases (FMOs) | en |
| dc.subject | Atherosclerosis | en |
| dc.title | 探討膳食化合物降低TMAO生成及減緩血管發炎之功效 | zh_TW |
| dc.title | The effects of dietary phenolic compounds on reducing trimethylamine-N-oxide formation and decreasing vascular inflammation in L-carnitine feeding mice | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 107-1 | |
| dc.description.degree | 碩士 | |
| dc.contributor.oralexamcommittee | 王應然(Ying-Jan Wang),黃步敏(Bu-Miin Huang),何元順(Yuan-Soon Ho),郭靜娟(Ching-Chuan Kuo) | |
| dc.subject.keyword | 動脈粥狀硬化,氧化三甲胺 (TMAO),肉鹼,腸道菌,膳食化合物, | zh_TW |
| dc.subject.keyword | Atherosclerosis,Trimethylamine-N-oxide (TMAO),Carnitine,Gut microbiota,Flavin monooxygenases (FMOs),Dietary phenolic compounds, | en |
| dc.relation.page | 76 | |
| dc.identifier.doi | 10.6342/NTU201900322 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2019-01-30 | |
| dc.contributor.author-college | 生物資源暨農學院 | zh_TW |
| dc.contributor.author-dept | 食品科技研究所 | zh_TW |
| 顯示於系所單位： | 食品科技研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-108-1.pdf 未授權公開取用 | 3.14 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。